Targeting critical regions in genomic DNA with AT-specific anticancer drugs
- 15 April 2002
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1587 (2-3), 300-308
- https://doi.org/10.1016/s0925-4439(02)00093-5
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Review: Nuclear Structure and DNA ReplicationJournal of Structural Biology, 2000
- Spatial Distribution of GC- and AT-Rich DNA Sequences within Human Chromosome TerritoriesExperimental Cell Research, 2000
- DNA Damage Produced by Enediynes in the Human Phosphoglycerate Kinase Gene in Vivo: Esperamicin A1 as a Nucleosome Footprinting AgentBiochemistry, 1998
- Mutagenic damage to mammalian cells by therapeutic alkylating agentsMutation Research, 1996
- Effects of Bizelesin (U-77779), a Bifunctional Alkylating Minor Groove Agent, on Genomic and Simian Virus 40 DNABiochemistry, 1995
- Effects of the DNA-Damaging Enediyne C-1027 on Intracellular SV40 and Genomic DNA in Green Monkey Kidney BSC-1 CellsBiochemistry, 1995
- The relevance of drug DNA sequence specificity to anti-tumour activityEuropean Journal Of Cancer, 1994
- Mapping of DNA Alkylation Sites Induced by Adozelesin and Bizelesin in Human Cells by Ligation-Mediated Polymerase Chain ReactionBiochemistry, 1994
- Phase I study of adozelesin (U-73,975) in patients with solid tumorsAnti-Cancer Drugs, 1994
- Chromosome Fragility and Instability in Human CancerCritical Reviews™ in Oncogenesis, 1994